67 related articles for article (PubMed ID: 20845478)
1. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Jabbour E; Kantarjian HM; O'Brien S; Shan J; Quintás-Cardama A; Garcia-Manero G; Rios MB; Cortes JE
J Clin Oncol; 2011 Nov; 29(32):4260-5. PubMed ID: 21990394
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
Jabbour EJ; Cortes JE; Kantarjian HM
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1433-52. PubMed ID: 24236822
[TBL] [Abstract][Full Text] [Related]
3. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.
Sasaki K; Strom SS; O'Brien S; Jabbour E; Ravandi F; Konopleva M; Borthakur G; Pemmaraju N; Daver N; Jain P; Pierce S; Kantarjian H; Cortes JE
Lancet Haematol; 2015 May; 2(5):e186-93. PubMed ID: 26688093
[TBL] [Abstract][Full Text] [Related]
4. Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
Ielo C; Scalzulli E; Carmosino I; Pepe S; Bisegna ML; Martelli M; Breccia M
Leuk Lymphoma; 2023 Dec; 64(14):2324-2326. PubMed ID: 37689986
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
Latifi Y; Moccetti F; Wu M; Xie A; Packwood W; Qi Y; Ozawa K; Shentu W; Brown E; Shirai T; McCarty OJ; Ruggeri Z; Moslehi J; Chen J; Druker BJ; López JA; Lindner JR
Blood; 2019 Apr; 133(14):1597-1606. PubMed ID: 30692122
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia: sequencing of TKI therapies.
Cortes J; Kantarjian H
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):164-169. PubMed ID: 27913476
[TBL] [Abstract][Full Text] [Related]
7. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
8. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
9. The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?
Zeidner JF; Zahurak M; Rosner GL; Gocke CD; Jones RJ; Smith BD
Leuk Lymphoma; 2015 Jan; 56(1):128-34. PubMed ID: 24712979
[TBL] [Abstract][Full Text] [Related]
10. How I treat newly diagnosed chronic phase CML.
Cortes J; Kantarjian H
Blood; 2012 Aug; 120(7):1390-7. PubMed ID: 22613793
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia: the race is yet to be won.
Cortes J
CMAJ; 2012 May; 184(8):857-8. PubMed ID: 22271914
[No Abstract] [Full Text] [Related]
12. Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.
Pavlík T; Janoušová E; Pospíšil Z; Mužík J; Záčková D; Ráčil Z; Klamová H; Cetkovský P; Trněný M; Mayer J; Dušek L
BMC Med Res Methodol; 2011 Oct; 11():140. PubMed ID: 21988861
[TBL] [Abstract][Full Text] [Related]
13. Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
Okimoto RA; Van Etten RA
Curr Opin Hematol; 2011 Mar; 18(2):89-97. PubMed ID: 21252655
[TBL] [Abstract][Full Text] [Related]
14. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Cortes J; Hochhaus A; Hughes T; Kantarjian H
J Clin Oncol; 2011 Feb; 29(5):524-31. PubMed ID: 21220597
[TBL] [Abstract][Full Text] [Related]
15. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Al-Kali A; Kantarjian H; Shan J; Bassett R; Quintás-Cardama A; Borthakur G; Jabbour E; Verstovsek S; O'Brien S; Cortes J
Cancer; 2011 Jan; 117(2):327-35. PubMed ID: 20845478
[TBL] [Abstract][Full Text] [Related]
16. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
17. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Hochhaus A; Druker B; Sawyers C; Guilhot F; Schiffer CA; Cortes J; Niederwieser DW; Gambacorti-Passerini C; Stone RM; Goldman J; Fischer T; O'Brien SG; Reiffers JJ; Mone M; Krahnke T; Talpaz M; Kantarjian HM
Blood; 2008 Feb; 111(3):1039-43. PubMed ID: 17932248
[TBL] [Abstract][Full Text] [Related]
18. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Ravandi F; Jabbour E; Shan J; Cortes J
Cancer; 2012 Jun; 118(12):3116-22. PubMed ID: 22370904
[TBL] [Abstract][Full Text] [Related]
19. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
